Rapamycin linked to DNA damage resilience in aging human immune cells
University of Oxford-led research finds low-dose rapamycin functions as a genomic protector in aging human immune cells, lowering DNA damage.
Medical Xpress
New study reveals hidden risks of ‘silent’ malaria infections
Researchers have uncovered new evidence that challenges long-standing beliefs about asymptomatic malaria infections. The study, led by Monash University’s Professor Diana Hansen and published in Molecular Systems Biology, focused on Plasmodium vivax, t…
Clinical trial suggests benefit of adjuvant chemo-immunotherapy in resected stage IB–IIIA NSCLC
Interim results from the NADIM ADJUVANT Phase III trial, led by the Spanish Lung Cancer Group (GECP), suggest that adjuvant chemo-immunotherapy may reduce the risk of recurrence in patients with completely resected stage IB–IIIA non-small cell lung can…
No OS benefit for concurrent and consolidative durvalumab vs. consolidation alone in unresectable stage 3 NSCLC: Trial
Treating patients who have stage III non-small cell lung cancer (NSCLC) with durvalumab concurrent with chemoradiotherapy (CRT) and continuing as consolidation therapy did not improve overall survival compared to consolidation durvalumab alone, accordi…
BMS-986504 demonstrates durable responses in MTAP-deleted NSCLC, including EGFR and ALK-positive tumors
BMS-986504, a first-in-class methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) targeting agent, showed promising antitumor activity in heavily pretreated patients with MTAP-deleted non-small cell lung cancer (NSCLC), ac…
Ifinatamab deruxtecan demonstrates high response rate in previously treated extensive-stage small cell lung cancer
Patients diagnosed with recurrent or progressive extensive-stage small cell lung cancer (ES-SCLC) may benefit from treatment with ifinatamab deruxtecan (I-DXd), a B7-H3–directed antibody–drug conjugate, according to data presented at the International …
First-in-human trial shows promising results for antibody-drug conjugate in relapsed small cell lung cancer
A first-in-human Phase I study of SHR-4849 (IDE849), a Delta-like ligand 3 (DLL3)-directed antibody-drug conjugate (ADC), demonstrated manageable safety and early signs of anti-tumor activity in patients with relapsed small cell lung cancer (SCLC).
Ivonescimab + chemotherapy improves progression-free survival in patients with EGFR+ NSCLC
Adding ivonescimab, a first-in-class bispecific antibody targeting both PD-1 and VEGF, to chemotherapy significantly prolonged progression-free survival (PFS) compared to chemotherapy alone in patients with advanced non-small cell lung cancer (NSCLC) h…
Trial shows osimertinib plus chemotherapy improves overall survival in EGFR-mutated advanced NSCLC
Final overall survival (OS) results from the Phase III FLAURA2 trial demonstrate that first-line osimertinib plus chemotherapy significantly improves OS compared to osimertinib monotherapy in patients with EGFR-mutated (EGFRm) advanced non-small cell l…
Nivolumab maintains quality of life and reduces symptom deterioration in resectable NSCLC, trial shows
An analysis from the Phase III CheckMate 77T trial confirms that perioperative nivolumab does not compromise health-related quality of life (HRQoL) in patients with resectable non-small cell lung cancer (NSCLC), including those with Stage III N2 disease.